OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation

Reuters12-10

<a href="https://laohu8.com/S/OSTX">OS Therapies</a> Unveils Cancer Immunotherapy Pipeline and Market <a href="https://laohu8.com/S/MSTR">Strategy</a> in New Presentation

OS Therapies Inc. has published a corporate presentation highlighting its clinical-stage pipeline and financial summary. The company reports over $300 million invested in its listeria immunotherapy platform, acquired from Advaxis/Ayala in April 2025. The lead program, OST-HER2, targets osteosarcoma and has potential follow-on applications in breast cancer and other solid tumors. The total addressable market for these assets is estimated at $258 billion. The company is targeting accelerated approval for OST-HER2 in human osteosarcoma between April and September 2026, with a projected Priority Review Voucher sale of approximately $160 million. The clinical pipeline also includes candidates for HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer. Current financials show a market cap of $60 million, cash holdings of approximately $4 million, and a monthly cash burn of about $300,000. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590535898?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590535898","market":"us","top_or_hot":-1,"title":"OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> Unveils Cancer Immunotherapy Pipeline and Market <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> in New Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc. has published a corporate presentation highlighting its clinical-stage pipeline and financial summary. The company reports over $300 million invested in its listeria immunotherapy platform, acquired from Advaxis/Ayala in April 2025. The lead program, OST-HER2, targets osteosarcoma and has potential follow-on applications in breast cancer and other solid tumors. The total addressable market for these assets is estimated at $258 billion. The company is targeting accelerated approval for OST-HER2 in human osteosarcoma between April and September 2026, with a projected Priority Review Voucher sale of approximately $160 million. The clinical pipeline also includes candidates for HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer. Current financials show a market cap of $60 million, cash holdings of approximately $4 million, and a monthly cash burn of about $300,000. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-10 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> Unveils Cancer Immunotherapy Pipeline and Market <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> in New Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc. has published a corporate presentation highlighting its clinical-stage pipeline and financial summary. The company reports over $300 million invested in its listeria immunotherapy platform, acquired from Advaxis/Ayala in April 2025. The lead program, OST-HER2, targets osteosarcoma and has potential follow-on applications in breast cancer and other solid tumors. The total addressable market for these assets is estimated at $258 billion. The company is targeting accelerated approval for OST-HER2 in human osteosarcoma between April and September 2026, with a projected Priority Review Voucher sale of approximately $160 million. The clinical pipeline also includes candidates for HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer. Current financials show a market cap of $60 million, cash holdings of approximately $4 million, and a monthly cash burn of about $300,000. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADXS","symbol_name":"Ayala Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLWhznZ:1","article_id":"2590535898","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590535898","pubTimestamp":1765378623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OS Therapies Inc. has published a corporate presentation highlighting its clinical-stage pipeline and financial summary. The company reports over $300 million invested in its listeria immunotherapy platform, acquired from Advaxis/Ayala in April 2025. The lead program, OST-HER2, targets osteosarcoma and has potential follow-on applications in breast cancer and other solid tumors. The total addressable market for these assets is estimated at $258 billion. The company is targeting accelerated approval for OST-HER2 in human osteosarcoma between April and September 2026, with a projected Priority Review Voucher sale of approximately $160 million. The clinical pipeline also includes candidates for HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer. Current financials show a market cap of $60 million, cash holdings of approximately $4 million, and a monthly cash burn of about $300,000. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADXS":"Ayala Pharmaceuticals, Inc.","OSTX":"OS Therapies","BK4139":"生物科技"},"translate_title":"OS Therapies在新演示中公布癌症免疫疗法管道和市场战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":0.9,"ADXS":0.9},"content_text":"OS Therapies Unveils Cancer Immunotherapy Pipeline and Market Strategy in New Presentation\n    \n\n        OS Therapies Inc. has published a corporate presentation highlighting its clinical-stage pipeline and financial summary. The company reports over $300 million invested in its listeria immunotherapy platform, acquired from Advaxis/Ayala in April 2025. The lead program, OST-HER2, targets osteosarcoma and has potential follow-on applications in breast cancer and other solid tumors. The total addressable market for these assets is estimated at $258 billion. The company is targeting accelerated approval for OST-HER2 in human osteosarcoma between April and September 2026, with a projected Priority Review Voucher sale of approximately $160 million. The clinical pipeline also includes candidates for HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer. Current financials show a market cap of $60 million, cash holdings of approximately $4 million, and a monthly cash burn of about $300,000. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590535898","isCrawlerRequest":true}